Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp. (KTTA) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · KTTA · as of Mar 31, 2025
Ownership Breakdown
7
Institutional Holders
$99,102
Total Inst. Value
▼ $144,171 vs Q4
7.44M
Shares Outstanding
freeFloat 98.36%
78,704
13F Shares Held
▲ 1,542 vs Q4
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
KTTA largest shareholders · institutional ownership
Q1 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
ADVISORSHARES INVESTMENTS LLC pharmaceutical preparations | 53.5K | 94.92% | 94.92% | $66.40M | May 13, 2025 | NEW |
CITIGROUP INC pharmaceutical preparations | 13.7K | 24.30% | 24.30% | $17.82M | May 12, 2025 | NEW |
UBS GROUP AG pharmaceutical preparations | 4.3K | 7.69% | 7.69% | $5.64M | May 13, 2025 | ▼ 8.5K |
HURLEY CAPITAL, LLC pharmaceutical preparations | 3.7K | 6.54% | 6.54% | $4.80M | May 7, 2025 | NEW |
TOWER RESEARCH CAPITAL LLC (TRC) pharmaceutical preparations | 3.3K | 5.79% | 5.79% | $4.25M | May 15, 2025 | ▲ 1.4K |
JPMORGAN CHASE & CO pharmaceutical preparations | 150 | 0.27% | 0.27% | $195,000 | May 12, 2025 | — held |
BANK OF AMERICA CORP /DE/ pharmaceutical preparations | 8 | 0.01% | 0.01% | $10,000 | May 15, 2025 | — held |
ROYAL BANK OF CANADA pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Nov 21, 2025 | EXIT |
MORGAN STANLEY pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | May 15, 2025 | EXIT |
ARMISTICE CAPITAL, LLC pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | May 15, 2025 | EXIT |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q1 2025 vs prior quarter
Q1 2025
1
Increased
+1.4K shares3
New Positions
first time holders1
Decreased
−8.5K shares3
Sold Out
fully exitedNet shares change (top 50)
7.2K
+1.4K / −8.5K
Net new holders
+0
3 new / 3 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
KTTA insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
2
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Marques Tiago Chief Executive Officer | May 1, 2026 | Award | 1,756,069 | $0.84 | $1.48M | 1.76M | Form 4 ↗ |
STEINMAN LAWRENCE director | May 1, 2026 | Award | 152,783 | $0.84 | $128.5K | 152.8K | Form 4 ↗ |
Dumesnil Simon director | May 1, 2026 | Award | 152,783 | $0.84 | $128.5K | 152.8K | Form 4 ↗ |
Schneiderman Daniel H Chief Financial Officer | May 1, 2026 | Award | 1,129,323 | $0.84 | $949.8K | 1.13M | Form 4 ↗ |
Krishnan Kartik Chief Medical Officer | May 1, 2026 | Award | 1,129,323 | $0.84 | $949.8K | 1.13M | Form 4 ↗ |
Leahy Emer director | May 1, 2026 | Award | 152,783 | $0.84 | $128.5K | 152.8K | Form 4 ↗ |
Novak Alfred J director | May 1, 2026 | Award | 152,783 | $0.84 | $128.5K | 152.8K | Form 4 ↗ |
STEINMAN LAWRENCE director | Nov 28, 2025 | Purchase | 133,333 | $0.75 | $100.0K | 199.7K | Form 4 ↗ |
Schneiderman Daniel H Chief Financial Officer | Nov 28, 2025 | Award | 26,667 | $0.75 | $20.0K | 26.7K | Form 4 ↗ |
Marques Tiago Chief Executive Officer | Nov 28, 2025 | Purchase | 33,333 | $0.75 | $25.0K | 73.3K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Pasithea Therapeutics Corp. (KTTA) is primarily owned by institutional investors, who hold approximately 1.1% of total shares outstanding. Company insiders own approximately 1.64%, while retail and public investors account for the remaining 97.30%.
The largest institutional shareholder of Pasithea Therapeutics Corp. is ADVISORSHARES INVESTMENTS LLC, holding approximately 53,547 shares — equal to 94.92% of outstanding shares — as of March 31, 2025.
A total of 7 institutional investors currently hold KTTA stock, with a combined institutional value of approximately $99,102 as of the most recent 13F filing period.
Frequently asked questions
KTTA ownershipPasithea Therapeutics Corp. (KTTA) is primarily owned by institutional investors, who hold approximately 1.1% of shares. The largest shareholder is ADVISORSHARES INVESTMENTS LLC with a 94.92% stake. Company insiders hold 1.64%. Data sourced from SEC Form 13F as of March 31, 2025.